Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.92
+0.1%
$14.81
$12.96
$20.90
$333.62M0.82101,443 shs105,805 shs
Immatics N.V. stock logo
IMTX
Immatics
$9.56
+0.4%
$10.57
$5.05
$12.41
$1.28B1.3500,034 shs331,278 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.81
+0.4%
$38.32
$25.33
$60.08
$1.29B0.47308,273 shs389,943 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$7.74
+0.7%
$6.45
$4.52
$10.08
$1.33B0.781.92 million shs2.58 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
+0.06%+0.70%+9.87%+10.10%+1.34%
Immatics N.V. stock logo
IMTX
Immatics
+0.42%-2.25%-16.94%-2.85%+76.06%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.38%+2.38%+3.31%-42.49%+23.97%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
+0.65%+12.17%+25.65%+33.45%+64.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.92
+0.1%
$14.81
$12.96
$20.90
$333.62M0.82101,443 shs105,805 shs
Immatics N.V. stock logo
IMTX
Immatics
$9.56
+0.4%
$10.57
$5.05
$12.41
$1.28B1.3500,034 shs331,278 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.81
+0.4%
$38.32
$25.33
$60.08
$1.29B0.47308,273 shs389,943 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$7.74
+0.7%
$6.45
$4.52
$10.08
$1.33B0.781.92 million shs2.58 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
+0.06%+0.70%+9.87%+10.10%+1.34%
Immatics N.V. stock logo
IMTX
Immatics
+0.42%-2.25%-16.94%-2.85%+76.06%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.38%+2.38%+3.31%-42.49%+23.97%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
+0.65%+12.17%+25.65%+33.45%+64.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
2.50
Moderate BuyN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
2.63
Moderate Buy$20.80117.57% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.00
Hold$42.5033.61% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.43
Hold$10.8039.53% Upside

Current Analyst Ratings Breakdown

Latest AMRN, XERS, PAHC, and IMTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2026
Immatics N.V. stock logo
IMTX
Immatics
DowngradeSell (D)Sell (D-)
6/16/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
UpgradeHoldStrong-Buy
6/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B-)Hold (C+)
6/9/2026
Immatics N.V. stock logo
IMTX
Immatics
Reiterated RatingSell (D)
5/21/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeStrong-BuyHold
5/19/2026
Immatics N.V. stock logo
IMTX
Immatics
Reiterated RatingBuy$25.00
5/18/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-BuyHold
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/11/2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
DowngradeHold (C-)Sell (D+)
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
4/28/2026
Immatics N.V. stock logo
IMTX
Immatics
Initiated CoverageBuy
(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$216.76M1.54$0.36 per share44.08$22.07 per share0.72
Immatics N.V. stock logo
IMTX
Immatics
$37.30M34.37N/AN/A$4.09 per share2.34
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.00$3.28 per share9.69$7.05 per share4.51
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$291.85M4.58$0.10 per share76.77$0.08 per share96.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)
Immatics N.V. stock logo
IMTX
Immatics
-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%8/12/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3313.659.550.486.35%37.14%8.57%6/30/2026 (Confirmed)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$550K$0.06129.0023.45N/A3.81%735.00%3.24%8/6/2026 (Estimated)

Latest AMRN, XERS, PAHC, and IMTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Immatics N.V. stock logo
IMTX
Immatics
-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million
5/7/2026Q1 2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.51%N/A20.60%N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Latest AMRN, XERS, PAHC, and IMTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.48
2.46
Immatics N.V. stock logo
IMTX
Immatics
N/A
8.78
8.78
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
17.00
2.12
1.50

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Immatics N.V. stock logo
IMTX
Immatics
64.41%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
Immatics N.V. stock logo
IMTX
Immatics
N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.97 million20.09 millionOptionable
Immatics N.V. stock logo
IMTX
Immatics
260134.07 millionN/AOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290172.64 million165.13 millionOptionable

Recent News About These Companies

Xeris Biopharma: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$15.92 +0.01 (+0.06%)
Closing price 06/29/2026 04:00 PM Eastern
Extended Trading
$15.98 +0.05 (+0.35%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Immatics stock logo

Immatics NASDAQ:IMTX

$9.56 +0.04 (+0.42%)
Closing price 06/29/2026 04:00 PM Eastern
Extended Trading
$9.73 +0.17 (+1.78%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.81 +0.12 (+0.38%)
Closing price 06/29/2026 04:00 PM Eastern
Extended Trading
$31.05 -0.76 (-2.39%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$7.74 +0.05 (+0.65%)
Closing price 06/29/2026 04:00 PM Eastern
Extended Trading
$7.68 -0.06 (-0.83%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.